Key Points AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful impact on Qulipta's sales. However, AbbVie's most important growth opportunities lie elsewhere. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) , a pharmaceutical giant, is best known for its work in immunology. Over the decade between 2013 (when it became a stand-alone publicly traded company) and 2023, the drugmaker's biggest growth driver was Humira, a medicine for several autoimmune disorders that was once the world's best-selling drug. Humira lost U.S. patent exclusivity in 2023, but since then, Skyrizi and Rinvoq, two other immunology medicines, have become AbbVie's growth pillars.
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.